Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) is scheduled to be announcing its earnings results before the market opens on Thursday, August 1st. Analysts expect the company to announce earnings of $1.05 per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.
Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) last posted its earnings results on Wednesday, May 1st. The company reported $0.42 earnings per share for the quarter, missing analysts’ consensus estimates of $1.04 by ($0.62). The firm had revenue of $515.30 million for the quarter, compared to analyst estimates of $512.21 million. Neurocrine Biosciences had a return on equity of 17.45% and a net margin of 18.65%. On average, analysts expect Neurocrine Biosciences to post $4 EPS for the current fiscal year and $7 EPS for the next fiscal year.
Neurocrine Biosciences Stock Performance
Shares of Neurocrine Biosciences stock opened at $141.18 on Wednesday. Neurocrine Biosciences has a 52-week low of $99.98 and a 52-week high of $150.39. The stock has a market cap of $14.21 billion, a PE ratio of 38.89 and a beta of 0.37. The firm has a 50-day moving average of $139.25 and a 200-day moving average of $138.13.
Analyst Ratings Changes
Check Out Our Latest Report on Neurocrine Biosciences
Insider Activity at Neurocrine Biosciences
In other news, CFO Matt Abernethy sold 15,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $140.24, for a total transaction of $2,103,600.00. Following the completion of the transaction, the chief financial officer now owns 31,528 shares of the company’s stock, valued at $4,421,486.72. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other news, Director Stephen A. Sherwin sold 40,000 shares of the firm’s stock in a transaction on Wednesday, May 29th. The shares were sold at an average price of $133.46, for a total transaction of $5,338,400.00. Following the completion of the transaction, the director now owns 26,504 shares of the company’s stock, valued at $3,537,223.84. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Matt Abernethy sold 15,000 shares of the firm’s stock in a transaction on Wednesday, May 15th. The shares were sold at an average price of $140.24, for a total transaction of $2,103,600.00. Following the transaction, the chief financial officer now directly owns 31,528 shares of the company’s stock, valued at approximately $4,421,486.72. The disclosure for this sale can be found here. Insiders sold a total of 80,709 shares of company stock valued at $11,009,150 in the last quarter. Insiders own 4.30% of the company’s stock.
Neurocrine Biosciences Company Profile
Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
Further Reading
- Five stocks we like better than Neurocrine Biosciences
- Insider Buying Explained: What Investors Need to Know
- AbbVie Analysts Lead the Stock Higher as Humira Worries Recede
- Manufacturing Stocks Investing
- Harley-Davidson Stock Revs Up With Billion Dollar Buyback Program
- Most Volatile Stocks, What Investors Need to Know
- Cruise Line Stock Sinks Despite Beating EPS and Raised Guidance
Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.